Research Projects & Grants

Federal

  • Targeting anti-angiogenesis in the treatment of actinic keratosis, Role: Principal Investigator, National Medical Technology Testbed, Inc., (02/2009 - 03/2011) Status: Closed

For Profit Organization

  • A phase 3, open-label study of the safety, efficacy, and tolerability of apomorphine administered by continuous subcutaneous infusion in advanced Parkinson's disease patients with unsatisfactory control on available therapy, Role: Investigator, U.S. World Meds, (11/2021 - 11/2022) Status: Completed
  • Protocol ML28296 (RegiSONIC) - A prospective observational study of treatment patterns and effectiveness and safety outcomes in advanced basal cell carcinoma nevus syndrome patients, Role: PI, Genentech, Inc., (05/2017 - 05/2018) Status: Completed
  • Placebo-controlled, double-blind study to assess efficacy and safety of oral vismodegib for the treatment of basal cell carcinoma preceding excision by Mohs micrographic surgery (MMS); version 3.0 dated February 22, 2012, Role: PI, Genentech, Inc., (07/2012 - 07/2013) Status: Completed
  • In Vivo confocal reflectance microscopy for pigmented lesion diagnosis: A multi-center study, Role: PI, Lucid, Inc., (10/2009 - 10/2010) Status: Completed
  • A multicenter, double-blind, randomized start, placebo-controlled, parallel-group study to assess rasagiline as a disease modifying therapy in early Parkinson's disease subjects. Protocol No.: TVP-1012/500 (ADAGIO), Role: Investigator, Teva Pharmaceutical Industries, Ltd., (09/2007 - 09/2008) Status: Completed
  • Determination of tumor margins in vivo using confocal microscopy prior to and confirmed by Mohs micrographic surgery, Role: PI, Lucid, Inc., (06/2007 - 06/2008) Status: Completed
  • Community based evaluation of combination therapy using Duac® topical gel and a retinoid (Retin-A Micro® 0.04%, Retin-A Micro® 0.1%, or Differin® gel 1.0%) in the treatment of moderate to severe acne vulgaris (DTG0607), Role: PI, Stiefel Laboratories, Inc., (07/2006 - 07/2007) Status: Completed
  • A multi-center, epidemiology study to evaluate the potential for adverse health effects in fetuses and live-born infants following a woman's pregnancy, compared with a similar group of psoriatic women not exposed to tazarotene and compared with background levels in general population., Role: Investigator, Allergan Inc., (01/2006 - 01/2007) Status: Completed
  • Comparison of confocal microscopy to conventional frozen section histology in Mohs micrographic surgery tissue evaluation, Role: PI, Lucid, Inc., (01/2006 - 01/2007) Status: Completed
  • A multi-center study to assess the impact of topical corticosteriods on the safety and efficacy of protopic (tacrolimus) ointment in the short-term treatment of atopic dermatitis and to assess protopic in the long-term management of atopic dermatitis, Role: Investigator, Fujisawa, (10/2005 - 10/2006) Status: Completed
  • Open-label study to evaluate the use of imiquimod 5% topical cream for reducing postsurgical recurrence or persistence of Basal Cell Carcinoma following excision by Curettage, Role: PI, 3M Pharmaceuticals, (10/2005 - 10/2006) Status: Completed
  • A Double-Blind, Randomized Study to Assess the Quality of Life and Cost of Disease in Patients with Herpes Zoster Treated with Famciclovir or Placebo, Role: PI, Smithkline Beecham, (06/1995 - 06/1996) Status: Completed
  • Vehicle-controlled, double-blind study to assess efficacy and safety of topical imiquimod 5% cream for the treatment of basal cell carcinoma preceding excision by Mohs Micrographic Surgery (MMS), Role: PI, 3M Pharmaceuticals, Status: Completed
  • A 6 month, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of ASM 981 (primecrolimus) cream 1% BID vs standard of care in management of mild to severe atopic dermatitis in children 3 months to 11 years, Role: Investigator, Novartis Pharma AG, Status: Completed
  • Double-blind, vehicle-controlled study to evaluate cellular and molecular events during four weeks of treatment for Actinic Keratoses with Aldara (imiquimod) cream, 5%, Role: PI, 3M Pharmaceuticals, Status: Completed
  • A Phase IIIb, open-label, multicenter study to evaluate the safety of 1.0 mg/kg subcutaneously administered Efalizumab in adults with moderate to severe plaque psoriasis, including those who are receiving concomitant antipsoriatic therapies or have recently transitioned from systemic therapies, Role: Investigator, Genentech, Inc., Status: Completed

Internal

  • Does the original method of which the diagnosis of melanoma is obtained affect outcome and overall treatment?, Role: PI, LLU Dept. of Dermatology, (05/2012 - 05/2013) Status: Completed
  • Targeting Anti-Angiogenesis in the Treatment of Actinic Keratosis, Role: Principal Investigator, LLU School of Medicine, (02/2009 - 03/2012) Status: Closed
  • Treatment of post-liposuction skin laxity (wrinkling) with thermage, Role: PI, LLU School of Medicine, (06/2006 - 06/2007) Status: Completed